MedTrace Logo

Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age

NCT06000397 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2024-04-09

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the effectiveness of enhanced email reminders in improving vaccine coverage at the 12-month visit in CANImmunize app users. The main questions it aims to answer are:

* Do enhanced email reminders improve coverage of the 12- month dose of the pneumococcal vaccine and the timely completion of its immunization series at the 12-month's visit in CANImmunize app users?
* What are the predictors of predictors of timely completion of the 12-month's series of pneumococcal vaccines in the CANImmunize app users?

Participants will be randomized to either receive enhanced reminder/recall materials via email or the standard CANImmunize notifications. Researchers will compare the enhanced reminder group to the standard notification group to see if there is a difference in vaccine coverage at the 12-month visit.

Conditions

  • Pneumococcal Vaccines
  • Immunization Coverage

Interventions

OTHER

Enhanced reminders

The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically: * Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine, * Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and * Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit

OTHER

Standard CANImmunize notifications

Push notifications at two time points: * two weeks prior to the immunization due date * one week after the immunization due date

Sponsors & Collaborators

  • Ottawa Hospital Research Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Months
Max Age
11 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-07
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06000397 on ClinicalTrials.gov